IB 
Union Calendar No. 270
108TH CONGRESS 
2D SESSION 
H. R. 3866
[Report No. 108–461, Parts I and II] 
To amend the Controlled Substances Act to provide increased penalties for 
anabolic steroid offenses near sports facilities, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 1, 2004
Mr. SENSENBRENNER (for himself, Mr. CONYERS, Mr. SWEENEY, Mr. 
OSBORNE, and Mr. BERMAN) introduced the following bill; which was re-
ferred to the Committee on the Judiciary, and in addition to the Com-
mittee on Energy and Commerce, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
APRIL 2, 2004
Reported from the Committee on the Judiciary with an amendment 
[Strike out all after the enacting clause and insert the part printed in italic] 
APRIL 2, 2004
Referral to the Committee on Energy and Commerce extended for a period 
ending not later than April 27, 2004
APRIL 27, 2004
Additional sponsors: Mr. SCOTT of Virginia, Mr. COBLE, Mr. STUPAK, Mr. 
MEEHAN, and Mr. CASTLE 
APRIL 27, 2004
Reported from the Committee on Energy and Commerce with an amendment
[Strike out all after the enacting clause and insert sections 1 through 4 printed in italic and 
insert the part printed in boldface roman] 
[For text of introduced bill, see copy of bill as introduced on March 1, 2004] 
A BILL 
To amend the Controlled Substances Act to provide increased 
penalties for anabolic steroid offenses near sports facili-
ties, and for other purposes.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Anabolic Steroid Control 
Act of 2004’’. 
SEC. 2. INCREASED PENALTIES FOR ANABOLIC STEROID 
OFFENSES NEAR SPORTS FACILITIES. 
(a) IN GENERAL.—Part D of the Controlled Substances 
Act is amended by adding at the end the following: 
ANABOLIC STEROID OFFENSES NEAR SPORTS FACILITIES 
‘‘SEC. 424. (a) Whoever violates section 401(a)(1) or 
section 416 by manufacturing, distributing, or possessing 
with intent to distribute, an anabolic steroid near or at a 
sports facility is subject to twice the maximum term of im-
prisonment, maximum fine, and maximum term of super-
vised release otherwise provided by section 401 for that of-
fense. 
‘‘(b) As used in this section—
‘‘(1) the term ‘sports facility’ means real prop-
erty where athletic sports or athletic training takes 
place, if such property is privately owned for com-
mercial purposes or if such property is publicly 
owned, but does not include any real property de-
scribed in section 419; 
‘‘(2) the term ‘near or at’ means in or on, or 
within 1000 feet of; and 
‘‘(3) the term ‘possessing with intent to dis-
tribute’ means possessing with the intent to distribute 
near or at a sports facility.’’. 
(b) TABLE OF CONTENTS AMENDMENT.—The table of 
contents for Comprehensive Drug Abuse Prevention and 
Control Act of 1970 is amended by inserting after the item 
relating to section 423 the following new item:
‘‘Sec. 424. Anabolic steroid offenses near sports facilities.’’.
SEC. 3. SENTENCING COMMISSION GUIDELINES. 
The United States Sentencing Commission shall—
(1) review the Federal sentencing guidelines with 
respect to offenses involving anabolic steroids; 
(2) consider amending the Federal sentencing 
guidelines to provide for increased penalties with re-
spect to offenses involving anabolic steroids in a man-
ner that reflects the seriousness of such offenses and 
the need to deter anabolic steroid use; and
(3) take such other action that the Commission 
considers necessary to carry out this section. 
SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) DEFINITIONS.—Section 102 of the Controlled Sub-
stances Act (21 U.S.C. 802) is amended—
(1) in paragraph (41)—
(A) by realigning the margin so as to align 
with paragraph (40); and 
(B) by striking subparagraph (A) and in-
serting the following: 
‘‘(A) The term ‘anabolic steroid’ means any drug or 
hormonal substance, chemically and pharmacologically re-
lated to testosterone (other than estrogens, progestins, 
corticosteroids, and dehydroepiandrosterone), and in-
cludes—
‘‘(i) androstanediol—
‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 
‘‘(II) 3α,17β-dihydroxy-5α-androstane; 
‘‘(ii) androstanedione (5α-androstan-3,17-dione); 
‘‘(iii) androstenediol—
‘‘(I) 1-androstenediol (3β,17β-dihydroxy-
5α-androst-1-ene); 
‘‘(II) 1-androstenediol (3α,17β-dihydroxy-
5α-androst-1-ene);
‘‘(III) 4-androstenediol (3β,17β-dihydroxy-
androst-4-ene); and 
‘‘(IV) 5-androstenediol (3β,17β-dihydroxy-
androst-5-ene); 
‘‘(iv) androstenedione—
‘‘(I) 1-androstenedione ([5α]-androst-1-en-
3,17-dione); 
‘‘(II) 4-androstenedione (androst-4-en-3,17-
dione); and 
‘‘(III) 5-androstenedione (androst-5-en-3,17-
dione);
‘‘(v) 
bolasterone 
(7α,17α-dimethyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene-
3-one); 
‘‘(vii) 
calusterone 
(7β,17α-dimethyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-
en-3-one); 
‘‘(ix) dehydrochlormethyltestosterone (4-chloro-
17β-hydroxy-17α-methylandrost-1,4-dien-3-one); 
‘‘(x) ∆1-dihydrotestosterone (also known as 1-tes-
tosterone) (17β-hydroxy-5α-androst-1-en-3-one); 
‘‘(xi) 
4-dihydrotestosterone 
(17β-hydroxy-
androstan-3-one);
‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α-
androstan-3-one); 
‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr-
4-ene); 
‘‘(xiv) 
fluoxymesterone 
(9-fluoro-17α-methyl-
11β,17β-dihydroxyandrost-4-en-3-one);
‘‘(xv) 
formebolone 
(2-formyl-17α-methyl-
11α,17β-dihydroxyandrost-1,4-dien-3-one); 
‘‘(xvi) 
furazabol 
(17α-methyl-17β-
hydroxyandrostano[2,3-c]-furazan); 
‘‘(xvii) 13α-ethyl-17β-hydroxygon-4-en-3-one; 
‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy-
androst-4-en-3-one); 
‘‘(xix) 
4-hydroxy-19-nortestosterone 
(4,17β-
dihydroxy-estr-4-en-3-one); 
‘‘(xx) mestanolone (17α-methyl-17β-hydroxy-5α-
androstan-3-one); 
‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy-[5α]-
androstan-3-one); 
‘‘(xxii) 
methandienone 
(17α-methyl-17β-
hydroxyandrost-1,4-dien-3-one); 
‘‘(xxiii) 
methandriol 
(17α-methyl-3β,17β-
dihydroxyandrost-5-ene); 
‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α-
androst-1-en-3-one);
‘‘(xxv) 
methyltestosterone 
(17α-methyl-17β-
hydroxyandrost-4-en-3-one); 
‘‘(xxvi) 
mibolerone 
(7α,17α-dimethyl-17β-
hydroxyestr-4-en-3-one); 
‘‘(xxvii) 17α-methyl-∆1-dihydrotestosterone (17 
β-hydroxy-17α-methyl-5α-androst-1-en-3-one) 
(also 
known as ‘17-α-methyl-1-testosterone’); 
‘‘(xxviii) nandrolone (17β-hydroxyestr-4-en-3-
one); 
‘‘(xxix) norandrostenediol—
‘‘(I) 
19-nor-4-androstenediol 
(3β, 
17β-
dihydroxyestr-4-ene); 
‘‘(II) 19-nor-4-androstenediol (3α, 17β-
dihydroxyestr-4-ene); 
‘‘(III) 19-nor-5-androstenediol (3β, 17β-
dihydroxyestr-5-ene); and 
‘‘(IV) 19-nor-5-androstenediol (3α, 17β-
dihydroxyestr-5-ene); 
‘‘(xxx) norandrostenedione—
‘‘(I) 
19-nor-4-androstenedione 
(estr-4-en-
3,17-dione); and 
‘‘(II) 19-nor-5-androstenedione (estr-5-en-
3,17-dione); 
‘‘(xxxi) 
norbolethone 
(13β,17α-diethyl-17β-
hydroxygon-4-en-3-one);
‘‘(xxxii) norclostebol (4-chloro-17β-hydroxyestr-4-
en-3-one); 
‘‘(xxxiii) 
norethandrolone 
(17α-ethyl-17β-
hydroxyestr-4-en-3-one); 
‘‘(xxxiv) oxandrolone (17α-methyl-17β-hydroxy-
2-oxa-[5α]-androstan-3-one);
‘‘(xxxv) 
oxymesterone 
(17α-methyl-4,17β-
dihydroxyandrost-4-en-3-one); 
‘‘(xxxvi) 
oxymetholone 
(17α-methyl-2-
hydroxymethylene-17β-hydroxy-[5α]-androstan-3-
one); 
‘‘(xxxvii) stanozolol (17α-methyl-17β-hydroxy-
[5α]-androst-2-eno[3,2-c]-pyrazole); 
‘‘(xxxviii) 
stenbolone 
(17β-hydroxy-2-methyl-
[5α]-androst-1-en-3-one); 
‘‘(xxxix) testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic acid lactone); 
‘‘(xl) testosterone (17β-hydroxyandrost-4-en-3-
one); 
‘‘(xli) 
tetrahydrogestrinone 
(13β,17α-diethyl-
17β-hydroxygon-4,9,11-trien-3-one); 
‘‘(xlii) trenbolone (17β-hydroxyestr-4,9,11-trien-
3-one); and 
‘‘(xliii) any salt, ester, or ether of a drug or sub-
stance described in this paragraph;’’; and
(2) in paragraph (44), by inserting ‘‘anabolic 
steroids,’’ after ‘‘marihuana,’’. 
(b) AUTHORITY
AND
CRITERIA
FOR
CLASSIFICA-
TION.—Section 201(g) of the Controlled Substances Act (21 
U.S.C. 811(g)) is amended—
(1) in paragraph (1), by striking ‘‘substance 
from a schedule if such substance’’ and inserting 
‘‘drug which contains a controlled substance from the 
application of titles II and III of the Comprehensive 
Drug Abuse Prevention and Control Act (21 U.S.C. 
802 et seq.) if such drug’’; and 
(2) in paragraph (3), by adding at the end the 
following: 
‘‘(C) Upon the recommendation of the Secretary 
of Health and Human Services, a compound, mix-
ture, or preparation which contains any anabolic 
steroid, which is intended for administration to a 
human being or an animal, and which, because of its 
concentration, preparation, formulation or delivery 
system, does not present any significant potential for 
abuse.’’. 
(c) ANABOLIC
STEROIDS
CONTROL
ACT.—Section 
1903 of the Anabolic Steroids Control Act of 1990 (Public 
Law 101–647; 21 U.S.C. 802 note) is amended—
(1) by striking subsection (a); and